文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 工程科技 > 材料科学 > Functional Gastrointestinal Disorders
侵权投诉

Functional Gastrointestinal Disorders

April2006PHARMACOLOGICANDPHARMACOKINETICASPECTSOFFGIDS1423

PreclinicalPharmacology,

Pharmacokinetics,andToxicologyRequiredforNovelTherapeuticAgents

Thissectionoutlinessomegeneralpharmacody-namic,pharmacokinetic,andsafetyaspectsthatareim-portantforthedevelopmentofnewdrugsforFGIDs.

ThePharmacodynamicTarget

Drugselectivity.Selectivityreferstotheabilityof

acompoundtointeractwithonlyonereceptorsubtype,leavingotherreceptorsunaffectedatconcentrationsachievedatclinicallyuseddosesandavoidingsideef-fects.Althoughthisde nitionwasconsideredkeyto ndingeffectiveneworexperimentalmedications,thereareseveralimportantpitfallsinthisapproach.

First,drugselectivityisarelativeconcept,andthetendencytolabeladrugasa“selective”ligandforagivenreceptorsubtypeignoresthefactthatasinglemolecule,attherapeuticdoses,mayhaveseveral,sometimesdiffer-ent,biologicaltargets.Forinstance,cisapridewasfoundtobeapartial5-HT4receptoragonist,20a5-HT3recep-torantagonist,andafairlypotentHERGK channelblocker.21

Thesecondpitfallisthat,becauseofthemultifactorialpathophysiologyofFGIDs,single-receptormodulatingdrugsmaybelesslikelytoachieveasubstantialthera-peuticgain.Inseveral elds,22evidencesuggeststhatbalancedmodulationofmultipletargetsmayprovideasuperiortherapeuticeffectandsideeffectpro lecom-paredwiththeactionofaselectiveligand.Rationalapproachesinwhichstructuralfeaturesfromselectiveligandsarecombinedhaveproduceddesignedmultipleligandsthatspanalargevarietyoftargets.22Akeychallengeinthedesignofaligandwithmultipleactionsistoachieveabalancedpotencyandactivityateachtargetofinterestandasuitablepharmacokineticpro le.Thelessselectivealigandis,theharderitistopredicttoxicity;oncetoxicityoccurs,itbecomesevenmoredif culttoprovideamechanisticexplanationforit.Thismayjeopardizethedevelopmentandregulatoryapprovalofsuchalessselectiveligand.

Third,itislikelythatthemechanismsresponsibleforsymptomsinFGIDsmaydifferfromonepatienttoanotherandasingletargetmaynotachieveadequateef cacyinapatientpopulation.Withtheselectiveap-proachtorelievingsymptomsorgroupsofsymptoms(eg,painandconstipationordiarrhea),experienceshowsthatprimaryclinicalendpointswereachievedin 70%ofpatientswithagentssuchastegaserodoralos-etron.23–25Thelackofef cacyisunlikelytore ectan

inadequatedosebecausephase2studiesdidnotsuggestahigherdosewasmoreeffective;hence,thereistheneedtoconsiderusingmultipletherapiesor“designed”mul-tipleligandstoenhancethebene t/riskratio.Forin-stance,a5-HT3receptorantagonistwithpartialagonistactionat5-HT4receptorsmaybelessconstipatingthanapure5-HT3receptorantagonist.Anotherexampleisprovidedbytachykininreceptorantagonists;ithasbeensuggestedthattheanalgesicef cacyandmotilityinhi-bitionofmulti-tachykininorpan-tachykininreceptorantagonistsaresuperiortothatofmonoreceptorantagonists.26,27

Pharmacodynamicversuspathophysiologictar-get.Whendrugstargetasinglereceptormechanism,

heterogeneityinpathophysiology(eg,dysmotilityvshy-persensitivity)hasanegativeimpactonthetherapeuticgainifpatientsarenotselectedonthebasisofthespeci cdisorder.Indeed,someofthedisappointingresultsofthepastdecadecanbeattributedtotheheterogeneityoffunctionaldisorders,lackofunderstandingofpathophys-iology,andlackofshort-termmechanisticstudiesthatcanpredictclinicaloutcome.Newdrugsshouldtargettheentirepathophysiologicmechanism(s)contributingtothefunctionaldisorderratherthanonlyanindividualpartoraspeci creceptor.Thus,nonselectiveagentsdesignedtomodulatemultipletargetsofthewholepathophysiologicprocess(eg,dysmotility,sensorydisor-der,in ammation)wouldbeadvantageousoverhighlyselectivemedicationsaddressingasinglemechanism.Appropriatepatientsubgroupsshouldberecruitedtoshowthetherapeuticpropertiesofamedication,al-thoughthismayreducethegeneralizabilityoftheresultsofthetrial.

Pharmacokinetics

Pharmacokineticsmayhelptoachievegutselec-tivity.Thisapproachisparticularlyrelevantwhentherearepotentialactionsoutsidethegut.Forexample,pe-ripherallyrestrictedopioidreceptorantagonistssuchasmethylnaltrexoneandalvimopandonotcrosstheblood-brainbarrierand,inaddition,haveveryloworalbio-availability.28,29Thisoffersthepotentialtomodulateintestinalmotilitywithoutsystemiceffects.Moreover,targeteddrugdeliverytothecolonwithpH-ortime-dependentrelease30,31orbacterialactivationofaprodrugofferpotentialnewapproachesforFGIDs.

Anotherimportantpharmacokineticpropertyisthelackofinteractionswithfoodorotherdrugs.CYP2D6(10%slowmetabolizersinthecommunity),CYP3A4,andCYP2C19areimportantisoenzymesbecauseoftheirinvolvementinthemetabolismofmanydrugsanddrug-druginteractions.Signi cantinteractionswiththeseen-

上一页第3页

你可能喜欢

热门文档

相关文档

  • Functional Gastrointestinal Disorders

    Functional Gastrointestinal Disorders -- New Answers to Old Questions Lin Chang, MD Introduction While much progress has been made in recent years in the ...

  • Functional Gastrointestinal Disorders2

    GASTROENTEROLOGY 2006;130:1435–1446 Gender, Age, Society, Culture, and the Patient’s Perspective in the Functional Gastrointestinal Disorders LIN CHANG,*,...

  • Functional Bowel Disorders

    Table 1. Functional Gastrointestinal Disorders C. Functional bowel disorders C1. Irritable bowel syndrome C2. Functional bloating C3. Functional constipation ...

  • Functional Anorectal Disorders

    Table 1. Functional Gastrointestinal Disorders F. Functional anorectal disorders F1. Functional fecal incontinence F2. Functional anorectal pain F2a. Chronic ...

  • Functional GI Disorders for the Psychiatrist

    Review Articles Functional Gastrointestinal Disorders: An Update for the Psychiatrist MICHAEL P. JONES, M.D., MICHAEL D. CROWELL, PH.D. KEVIN W. OLDEN...

  • Functional Esophageal Disorders

    Functional Gastrointestinal Disorders A. Functional esophageal disorders A1. Functional heartburn A2. Functional chest pain of presumed esophageal origin A3. ...

  • Functional Constipation

    Among these, functional gastrointestinal disorders (FGIDs) are predominant: a heterogeneous group of chronic diseases that are believed not to have structural ...

  • 慢性便秘指南的修订与解读_方秀才

    弛不够或排便时推进力不足的客观证据 Rome III: the functional gastrointestinal disorders Drossman DA. 2006: 639 便秘严重程度的判断依据便秘及有关症状轻重度...

  • 促胃肠动力中药

    胃肠动力中药的研究 王平 wangping0632@yahoo.com.cn 功能性胃肠病 (functional gastrointestinal disorders, FGID) 胃肠动力性疾病 (disorders of gastrointestinal ...

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email